Appendix A: Supplementary data Table A1. Association of PD-L1 expression with patient and disease characteristics. antibody PD-L1Low, n/N Study name Evidence and study phase/design Cut-off for PD-L1 positivity Category PD-L1High, n/N (%) p-value (%) Age Epidermal growth factor receptor tyrosine kinase inhibitor years 22/30 (73.3) 18/26 (69.2) Anti-PD-L1, ab58810 ≤65 Lin 2015 [1] Preliminary: Prospective Mean H scores 0.735 (Abcam®) >65 years 8/30 (26.7) 8/26 (30.8) years 28/112 (25.0) 17/58 (29.3) Rabbit monoclonal ≤50 Tang 2015 [2] Preliminary: Consecutive >5% 0.546 anti-human antibody >50 84/112 (75.0) 41/58 (70.7) Chemotherapy/radiotherapy Sorensen 2014a Proportion trial of 3+ defined as strong <65 years 23/51 (45.1)b 27/51 (52.9) Clone 22C3 mouse Preliminary: retrospective / Abstract 0.65 [3] intensity monoclonal antibody years 28/51 (54.9)b 24/51 (47.1) ≥65 Rabbit polyclonal No significant association of PD-L1 2015 [4] Preliminary: Consecutive NR All 0.188 antibody ab156361 expression with age <70 years 49 (23%)c Clone E1L3N®, #13684 rabbit IgG Schmidt 2015 [5] Preliminary: Retrospective >5% 0.580 Cell Signaling years 28 (26%)c ≥70 Technology Gender Epidermal growth factor receptor tyrosine kinase inhibitor D'Incecco 2015 [6] Preliminary: Retrospective Male 36/68 (52.9) 30/55 (54.5)
Appendix A: Supplementary data Table A1. Association of PD-L1 expression with patient and disease characteristics. Study name Evidence and study phase/design Cut-off for PD-L1 positivity Category PD-L1High, n/N (%) PD-L1Low, n/N (%) p-value antibody Age Epidermal growth factor receptor tyrosine kinase inhibitor Lin 2015 [1] Preliminary: Prospective Mean H scores ≤65 years 22/30 (73.3) 18/26 (69.2) 0.735 Anti-PD-L1, ab58810 (Abcam®) >65 years 8/30 (26.7) 8/26 (30.8) Tang 2015 [2] Preliminary: Consecutive >5% ≤50 years 28/112 (25.0) 17/58 (29.3) 0.546 Rabbit monoclonal anti-human antibody >50 84/112 (75.0) 41/58 (70.7) Chemotherapy/radiotherapy Sorensen 2014a [3] Preliminary: retrospective / Abstract Proportion of 3+ defined as strong intensity <65 years 23/51 (45.1)b 27/51 (52.9) 0.65 Clone 22C3 mouse monoclonal antibody ≥65 years 28/51 (54.9)b 24/51 (47.1) 2015 [4] Preliminary: Consecutive NR All No significant association of PD-L1 expression with age 0.188 Rabbit polyclonal antibody ab156361 Schmidt 2015 [5] Preliminary: Retrospective >5% <70 years 49 (23%)c 0.580 Clone E1L3N®, #13684 rabbit IgG Cell Signaling Technology ≥70 years 28 (26%)c Gender Epidermal growth factor receptor tyrosine kinase inhibitor D'Incecco 2015 [6] Preliminary: Retrospective Male 36/68 (52.9) 30/55 (54.5) trial
1-s2.0-S0169500217304440-mmc1.docx